Literature DB >> 16247636

[Preoperative evaluation of prognostic factors in esophageal squamous cell cancer].

P M Schneider1, D Vallböhmer, J Brabender, A H Hölscher.   

Abstract

Despite substantial improvements in the surgical therapy of esophageal squamous cell cancer, the prognosis still remains poor. This is mainly due to locally advanced tumors (T3-4, N+) or systemic metastases (M1) in the majority of patients at initial presentation. It is of the utmost importance to reliably detect relevant pretherapeutic prognostic indicators for optimal individual therapeutic strategies. Pretherapeutic prognostic indicators should therefore discriminate precisely between incurable and potentially curative disease. Preoperative or definitive multimodal treatment is increasingly being offered to patients with locally advanced tumors and opens a broad field for innovative techniques such as pretherapeutic molecular response prediction or early response detection by PET scan to further individualize and optimize treatment strategies.

Entities:  

Mesh:

Year:  2005        PMID: 16247636     DOI: 10.1007/s00104-005-1109-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  38 in total

Review 1.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.

Authors:  Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

2.  [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].

Authors:  A H Hölscher; R Metzger; P M Schneider
Journal:  Zentralbl Chir       Date:  2000       Impact factor: 0.942

3.  [Pretherapeutic evaluation in cancer of the cardia].

Authors:  R Bardini; G Sovernigo; C Castoro
Journal:  J Chir (Paris)       Date:  1997-11

4.  Assessment of resectability of esophageal cancer by computed tomography and magnetic resonance imaging.

Authors:  L Lehr; N Rupp; J R Siewert
Journal:  Surgery       Date:  1988-03       Impact factor: 3.982

5.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

6.  The number of lymph node metastases influences survival in esophageal cancer.

Authors:  K Kawahara; T Maekawa; K Okabayashi; T Shiraishi; Y Yoshinaga; S Yoneda; T Hideshima; T Shirakusa
Journal:  J Surg Oncol       Date:  1998-03       Impact factor: 3.454

7.  Bronchoscopic staging of squamous cell carcinoma of the upper thoracic esophagus.

Authors:  A Baisi; L Bonavina; A Peracchia
Journal:  Arch Surg       Date:  1999-02

8.  Extended radical esophagectomy for superficially invasive carcinoma of the esophagus.

Authors:  T Nishimaki; T Suzuki; T Kanda; I Obinata; S Komukai; K Hatakeyama
Journal:  Surgery       Date:  1999-02       Impact factor: 3.982

9.  Preoperative lymph-node staging in gastrointestinal cancer--correlation between size and tumor stage.

Authors:  S P Mönig; W Schröder; S E Baldus; A H Hölscher
Journal:  Onkologie       Date:  2002-08

Review 10.  Locally advanced esophageal cancer.

Authors:  Carol A Sherman; Andrew T Turrisi; Michael B Wallace; Carolyn E Reed
Journal:  Curr Treat Options Oncol       Date:  2002-12
View more
  1 in total

1.  Web-Based Immersive Virtual Patient Simulators: Positive Effect on Clinical Reasoning in Medical Education.

Authors:  Robert Kleinert; Nadine Heiermann; Patrick Sven Plum; Roger Wahba; De-Hua Chang; Martin Maus; Seung-Hun Chon; Arnulf H Hoelscher; Dirk Ludger Stippel
Journal:  J Med Internet Res       Date:  2015-11-17       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.